New hope for stomach cancer patients: targeted chemo combo shows promise
NCT ID NCT04762953
First seen Feb 03, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study tests a treatment for stomach cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis). About 40 adults who have already had at least 3 months of standard chemotherapy will receive a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy (paclitaxel, 5-FU, leucovorin). The goal is to see if this approach can delay cancer growth and improve survival, while monitoring side effects. This is a phase 2 trial, meaning it is still being tested for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.